IVERIC bio (NASDAQ:ISEE) released its quarterly earnings results on Thursday. The company reported ($0.35) EPS for the quarter, Morningstar.com reports.
Shares of IVERIC bio stock traded down $0.01 during midday trading on Friday, hitting $1.16. The company had a trading volume of 221,062 shares, compared to its average volume of 78,342. The company’s 50 day moving average price is $1.25. The company has a market cap of $49.36 million, a PE ratio of -0.69 and a beta of 1.17. IVERIC bio has a 1-year low of $1.02 and a 1-year high of $2.60.
In related news, insider Glenn Sblendorio acquired 25,000 shares of the stock in a transaction dated Friday, May 10th. The shares were acquired at an average price of $1.48 per share, for a total transaction of $37,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.30% of the company’s stock.
A number of equities analysts have recently commented on ISEE shares. Zacks Investment Research lowered shares of IVERIC bio from a “hold” rating to a “sell” rating in a research report on Tuesday, June 4th. ValuEngine raised shares of IVERIC bio from a “hold” rating to a “buy” rating in a research report on Thursday.
About IVERIC bio
IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).
Further Reading: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.